The FDA on December 19, 2017 granted regular approval to CABOMETYX® for treatment of patients with advanced Renal Cell Carcinoma (RCC). CABOMETYX® is a product of Exelixis, Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on December 19, 2017 granted regular approval to CABOMETYX® for treatment of patients with advanced Renal Cell Carcinoma (RCC). CABOMETYX® is a product of Exelixis, Inc.
Advertisement